CBD for children with hard-to-treat epilepsy
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 18 years old.
- Your child has epilepsy that doesn't improve with standard treatments.
- Your child has at least 4 seizures during a 4-week check period.
- Your child's current seizure medicines have been stable for the past month.
- You are willing to keep your child on the same medicines during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at children with epilepsy to find out what makes some cases harder to treat with medicine. It may help doctors understand why seizures continue in some kids.
This study looks at how well the ketogenic diet (a high-fat, low-carb diet) works for children with epilepsy that doesn't improve with standard medicines. It uses a special product called KetoCal to help maintain the diet and tracks results in real life.
This trial tests if cannabinoids can help people who still have seizures despite trying two or more standard seizure medications. It aims to reduce seizure frequency in those with drug-resistant epilepsy.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This study tests a new CBD oil (CBD-OS) to see if it safely reduces seizures in people with developmental and epileptic encephalopathy (DEE), a condition where both development and seizure control are affected. Participants must already be on a stable antiseizure treatment.
Hear when a new Refractory Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.